Proprietary tissue integrity preservation technology mitigates residual aldehydes. This enables dry storage that simplifies handling.
Excellent outcomes through 7 years
RESILIA tissue data from the COMMENCE aortic trial show:
- 85.4% freedom from all-cause mortality through 7 years
- 99.3% freedom from structural valve deterioration through 7 years
- Clinically stable hemodynamics
- Effective orifice area was 1.82 ± 0.57 cm2
- Mean gradient was 9.4 ± 4.5 mmHg
To read about the results, patient demographics, study methods, and key points, download the COMMENCE aortic trial 7-year clinical summary.
Proven performance at 7 years
With excellent outcomes through 7 years, the COMMENCE trial demonstrates encouraging results for bioprostheses with RESILIA tissue.
Discover the difference with RESILIA Tissue
RESILIA tissue offers enhanced anti-calcification technology that will potentially allow the valve to last longer than conventional bioprosthetic valves2.
7-year data from the COMMENCE aortic trial represent the longest follow-up after aortic valve replacement with this novel tissue in a large IDE trial.
The COMMENCE trial 7-year data is only part of the clinical story
Our trials aim to build upon one another by adding new variables which further challenge valve safety and efficacy. Our COMMENCE trial increased the patient population from the EU Feasibility trial, and the RESILIENCE trial is designed to look at different outcome measures to help further establish long term valve durability.
See the growing body of RESILIA tissue data by visiting the Inspiring Results page.